LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) expressing malignancies, including gastric, lung, cervical and triple negative breast cancers. The investigator-initiated phase 1 trials are intended to evaluate the safety and tolerability with dose escalation of the autologous TCR-T cells targeting KK-LC-1. The investigators are now actively recruiting participants who have failed first-line therapy for the above-referenced solid tumors.
T-Cure licensed the commercial rights of the KK-LC-1 TCR-T therapy and entered into a Cooperative Research and Development Agreement (CRADA) with the NCI in 2020. The Company also initiated pre-clinical and clinical studies on KK-LC-1 TCR-T with Rutgers University in 2021.
“We have been working with the principal investigator at Rutgers University, Dr. Christian Hinrichs, and the NCI, Drs. James Gulley and Scott Norberg for a couple of years. We are extremely excited to see both sites have received IND clearance from the FDA, and are now open for recruitment”, stated Gang Zeng, Ph.D., Chief Executive Officer of T-Cure. “Our investigators are key opinion leaders of the cell therapy field. We are fortunate to work together to advance this novel TCR product candidate through the first ever clinical development in the world.”
Patients entering the trial are selected based on their expression of the KK-LC-1 antigen as determined by an immunohistochemistry assay. This assay was developed by T-Cure and validated for use in the ongoing trials.
Of note, the KK-LC-1 TCR was isolated from the tumor-infiltrating lymphocytes of a patient who had a complete response to immunotherapy without any toxicities. KK-LC-1 is a unique target and cannot be readily targeted by antibody, chimeric antigen receptor (CAR), or antibody drug conjugate (ADC) therapies. Trials at Rutgers University and NCI (clinicaltrials.gov link) are first-in-human targeting KK-LC-1 for multiple solid tumors.
About T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer. The Company focuses on isolating high avidity TCR that can be used to engineer a patient’s T cells to effectively target and destroy solid tumors. The Company maintains a pipeline of TCR therapies under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. More information is available at www.T-Cure.com.
Forward Looking Statements
T-Cure cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may”, “might”, “will”, “should”, “could”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “project”, “intend”, “future”, “potential” or “continue”, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
T-Cure Bioscience, Inc. IR & Media Contact
Chrystal Torry